Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
The present invention features benzothiazines that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms, and that have the formula: The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
1. A compound having the formula:
wherein,
Q is S—(CHR 6 ) 1 ;
R 1 and each R 6 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, optionally substituted C 2-9 heterocyclyl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 1-4 alkcycloalkyl, or —(CR 1A R 1B ) n NR 1C R 1D ;
R 1A and R 1B are, independently, H, hydroxy, halo, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 1-4 alkcycloalkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, optionally substituted C 1-4 alkheteroaryl, optionally substituted C 3-8 cycloalkyl, or optionally substituted C 2-9 heterocyclyl, or R 1A and R 1B combine to form ═O;
R 1C and R 1D are, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 1-4 alkcycloalkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, optionally substituted C 1-4 alkheteroaryl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 2-9 heterocyclyl, or an N-protecting group selected from the group consisting of formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, alaninyl, leucinyl, phenylalaninyl, benzenesulfonyl, p-toluenesulfonyl, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, benzyl, triphenylmethyl, benzyloxymethyl, and trimethylsilyl, or R 1C and R 1D combine to form an optionally substituted C 2-9 heterocyclyl;
n is an integer between 1-6;
each of R 2 and R 3 is, independently, H, hal, optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl, optionally substituted C 1-6 alkaryl, optionally substituted C 2-9 heterocyclyl, hydroxy, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 thioalkoxy, or NHC(NH)R 2A , or optionally substituted C 1-4 alkheterocyclyl,
wherein R 2A is
wherein X 2 is O or S;
each of R 4 and R 5 is independently H, hal, or NHC(NH)R 2A ;
wherein Y 1 and Y 2 are each H, or Y 1 and Y 2 together are ═O, or Y 1 and Y 2 are independently H, optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl, optionally substituted C 1-6 alkaryl, optionally substituted C 2-9 heterocyclyl, hydroxy, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 thioalkoxy, or optionally substituted C 1-4 alkheterocyclyl;
wherein one and only one of R 2 , R 3 , R 4 , and R 5 is NHC(NH)R 2A ;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein
R 1 and each R 6 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, or optionally substituted C 2-9 heterocyclyl.
3. The compound of claim 1 , wherein said compound has a structure selected from
4. The compound of claim 1 , wherein Y 1 and Y 2 are each H.
5. The compound of claim 1 , wherein Y 1 and Y 2 together are ═O.
6. The compound of claim 1 , wherein R 1 is optionally substituted C 1-6 alkyl, optionally substituted C 2-9 heterocyclyl, or optionally substituted C 1-4 alkheterocyclyl.
7. The compound of claim 6 , wherein R 1 is optionally substituted aminoC 1-6 alkyl.
8. The compound of claim 6 , wherein R 1 is optionally substituted C 1-4 alkheterocyclyl, wherein said heterocyclyl is a 5- or 6-membered cyclic amine.
9. The compound of claim 8 , wherein said cyclic amine is substituted with a carboxyl, C 1-6 alkoxycarbonyl, or carbamoyl group.
10. The compound of claim 6 , wherein R 1 is an optionally substituted C 2-9 heterocyclyl.
11. The compound of claim 10 , wherein said heterocyclyl is optionally substituted pyrrolidinyl or optionally substituted piperidinyl.
12. The compound of claim 11 , wherein R 1 is
wherein R 9 is H, optionally substituted C 1-6 alkyl, or optionally substituted C 1-4 alkaryl.
13. The compound of claim 12 , wherein R 9 is H.
14. The compound of claim 1 , wherein R 1 is an optionally substituted C 3 -C 8 cycloalkyl.
15. The compound of claim 1 , wherein R 1 is —(CR 1A R 1B ) n NR 1C R 1D .
16. The compound of claim 15 , wherein R 1A and R 1B are each H, and n is 2 or 3.
17. The compound of claim 15 , wherein R 1C is H, and R 1D is —CH 3 , —CH 2 CH 3 , —(CH 2 ) 2 OH, or —CH 2 CO 2 H; or R 1C and R 1D combine to form optionally substituted pyrrolidinyl or optionally substituted piperidinyl.
18. The compound of claim 15 , wherein R 1 is —CH 2 CH 2 N(CH 3 ) 2 or —CH 2 CH 2 NHCH 3 .
19. The compound of claim 14 , wherein said C 3 -C 8 cycloalkyl is substituted by an amino.
20. The compound of claim 1 , wherein one of R 4 or R 5 is H or F.
21. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
22. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
24. A pharmaceutical composition comprising the compound of claim 22 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
25. The compound of claim 22 , wherein said compound is the dihydrochloride salt.